Compare Amphastar Pharmaceuticals Inc (AMPH) vs Vital Farms Inc (VITL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Vital Farms (VITL) trades at $12.95, down 0.08% on the day, with a bullish technical signal supported by moving averages but overbought RSI readings. The stock shows solid profitability with a 6.1% net margin and 15.44% ROE, though earnings missed expectations in two recent quarters. Valuation appears reasonable with a P/E of 12.45 and P/S of 0.75. Recent news highlights volatility, including a class-action lawsuit filed in May 2026, while cash flow trends indicate significant investing outflows.

The outlook is mixed: analyst consensus leans bullish with a $13.50 price target, but risks include legal overhangs, earnings volatility, and negative cash flow. Revenue growth is modest, projected at $784M for 2026, but profit margins are declining. Investors should weigh strong fundamentals against near-term headwinds from litigation and operational challenges.